Clinical Trials

  • Principal Investigator:

    Stergios Zacharoulis, MD
    The purpose of this study is to find out more about how the study drug called talimogene laherparepvec will be used in children/adolescents/young adults with advanced solid tumors not involving the central nervous system that are available for direct injection. This is a phase 1 study, multicenter, open-label study, that means all subject enrolled in the study will be assigned talimogene laherparepvec. The study drug is a genetically modified virus. The virus' genes were modified in a laboratory to make the virus active in the tumor cell but not in normal cell. Talimogene laherparepvec is...
  • Principal Investigator:

    Luca Szalontay, MD
    This study will enroll children from 6 months to 17 years old that have solid tumor cancers or lymphoma (cancer of the cells in the lymph nodes, part of the body's immune system). The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) as well as look for the highest dose of pembrolizumab that can be given safely without serious side effects. This study will also attempt to find out how pembrolizumab is absorbed and broken down and determine how treatment with pembrolizumab may benefit children with cancer.
  • Principal Investigator:

    Marc E. Richmond, MD
    Patients with hypoplastic left heart syndrome and other single right ventricle lesions who have undergone the Fontan procedure have a high risk of neurodevelopmental disorders that affect quality of life and adulthood employment. This study will leverage the ongoing National Heart, Lung, and Blood Institute (NHLBI)-funded Single Ventricle Reconstruction Study by using innovative graph measures of brain connectivity to elucidate how alterations of the "connectome" in children with critical congenital heart disease are associated with developmental disabilities and their associated clinical...
  • Principal Investigator:

    Wendy Kay Chung, MD
    Study examining the genetic causes of birth defects.
  • Principal Investigator:

    Wendy Kay Chung, MD
    Study examining the genetic causes of birth defects.
  • Principal Investigator:

    Dani Dumitriu, MD
    The goal of this study is to address differences in health outcomes of newborns born to COVID positive versus case-matched COVID negative mothers, as well as mothers who gave birth immediately prior to the pandemic arriving in NYC (February 2020) through review of charts and surveys with mothers. Additionally, the study will distribute a survey to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic.
  • Principal Investigator:

    Dani Dumitriu, MD
    The goal of this study is to address differences in health outcomes of newborns born to COVID positive versus case-matched COVID negative mothers, as well as mothers who gave birth immediately prior to the pandemic arriving in NYC (February 2020) through review of charts and surveys with mothers. Additionally, the study will distribute a survey to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic.
  • Principal Investigator:

    Wendy Kay Chung, MD
    Each year more than 1,000 babies in the United States are born with a Congential Diaphragmatic Hernia (CDH). For the majority of these babies, the cause of the CDH is unknown. DHREAMS (Diaphragmatic Hernia Research & Exploration; Advancing Molecular Science) study was created to improve the understanding of the molecular genetic basis of CDH. This National Institute of Health (NIH)-funded research team is composed of health care providers and researchers across the country, coordinated at Columbia University Medical Center. Multiple medical centers are enrolling individuals and families...
  • Principal Investigator:

    Rakesh Sahni, MD
    The purpose of this study is to see if the use of bubble nasal continuous positive airway pressure (NCPAP) at a pressure of 6-7 centimeters of water (cm H2O) in very low birth weight (VLBW) infants is associated with improved gas exchange without any related changes in vital signs.
  • Principal Investigator:

    Stephanie Levasseur, MD
    Although supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The purpose of the FAST Research study is to improve the care of pregnancies affected by AF or SVT. The aim of the FAST Registry is to record the treatment your doctor prescribes, your ongoing care, and the outcome of your...

Pages